Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer

Table 6 Predictive factors for complete pathological response in univariate logistic regression analysis for the capecitabine/deGramont-RT regimen

Variable		Non-pCR (n = 102) n P50 (P25-P75)	pCR (n = 13) n P50 (P25-P75)	pCR rate	P-value
Gender	Male	70	6	7.89%	0.096
	Female	31	7	18.42%
Age (yr)	≤ 60	56	10	15.15%	0.131
	> 60	46	3	6.12%
BMI (kg/cm2)	< 25	75	8	9.64%	0.375
	≥ 25	21	4	16.00%
Hemoglobin (g/L)	≤ 125	33	1	2.94%	0.087
	> 125	56	9	13.85%
NLR	> 3	12	4	25.00%	0.031
	≤ 3	77	6	7.23%
PLT (×109/L)		228 (188.25-266.75)	252 (188.75-319)		0.338
ApoA1 (g/L)		1.3 (1.14-1.48)	1.34 (1.11-1.46)		0.912
ApoB (g/L)		0.97 (0.8-1.09)	0.92 (0.78-1.02)		0.667
The interval		53.97 ± 8.94	52.38 ± 10.79		0.588
CEA (ng/mL)	> 5	51	5	8.93%	0.659
	≤ 5	38	5	11.63%
Differentiation	Moderate-poor	82	8	8.89%	0.177
	Well	17	4	19.05%
DTAV (cm)	< 5	52	9	14.75%	0.214
	≥ 5	50	4	7.41%
TL (cm)	> 3	74	8	9.76%	0.252
	≤ 3	23	5	17.86%
TCE	≤ 50%	10	0	0.00%	0.241
	> 50%	79	11	12.22%
cT	2	7	2	22.22%	0.521
	3	75	10	11.76%
	4	14	1	6.67%
cN	+	73	11	13.10%	0.394
	-	26	2	7.14%
MRF	-	74	11	12.94%	0.377
	+	27	2	6.90%

Platelet, apolipoprotein A-1, apolipoprotein B, and the interval were calculated as metrological data, and others are counting data. pCR: Complete pathological response; NLR: Neutrophil-lymphocyte ratio; DTAV: Distance of tumor from the anal verge; TL: Tumor length; TCE: Tumor circumferential extent; PLT: Platelet; ApoA1: Apolipoprotein A-1; ApoB: Apolipoprotein B; MRF: Mesorectal fascia; CEA: Carcinoembryonic antigen.